Applicability, Tolerability and Efficacy of Preemptive Antiviral Therapy in Hepatitis C-Infected Patients Undergoing Liver Transplantation

2006 ◽  
Vol 2006 ◽  
pp. 270-272
Author(s):  
A. Burke
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Antiviral Therapy

scholarly journals Serum Aspartate Aminotransferase Level and Previous Histopathological Findings Enable Reduction of Protocol Liver Biopsies after Liver Transplantation for Hepatitis C

2013 ◽  
Vol 27 (3) ◽  
pp. 131-136 ◽  
Author(s):  
Tomohiro Tanaka ◽  
George Therapondos ◽  
Nazia Selzner ◽  
Eberhard L Renner ◽  
Leslie B Lilly
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Aspartate Aminotransferase ◽  
Aminotransferase Level ◽  
Fibrosis Stage ◽  
Protocol Biopsy ◽  
Serum Aspartate Aminotransferase ◽  
Histological Activity ◽  
Liver Biopsies

BACKGROUND: Hepatitis C virus (HCV) infection remains the leading indication for liver transplantation (LT) worldwide. Recurrent hepatitis C following LT is universal, and significant fibrosis (SF, Metavir fibrosis stage ≥2) apparent on protocol biopsy typically prompts antiviral therapy.OBJECTIVE: To determine the optimal timing of protocol liver biopsies in this setting.METHODS: A total of 151 patients who underwent LT related to HCV infection between July 2004 and December 2009 were analyzed retrospectively. Data regarding protocol liver biopsies at six, 12 and 24 months post-LT, conventional laboratory parameters and demographic information were obtained.RESULTS: The 151 patients included in the present study had significantly lower serum aspartate aminotransferase (AST) levels than the four patients who progressed to receive antiviral treatment for SF before six months post-LT (P<0.001). AST level, but not alanine aminotransferase level, histological activity or fibrosis stage at the six-month biopsy was independently associated with the progression to SF at 12 months (P<0.05). However, AST level, histological activity and fibrosis stage at the 12-month biopsy emerged as independent parameters associated with progression to SF at 24 months (P<0.05).CONCLUSION: The protocol liver biopsy at six months could be eliminated, especially in patients who consistently exhibit low AST levels. Histological activity, the presence or absence of fibrosis, and AST values at the 12-month biopsy may lead to the decision to defer the protocol biopsy at 24 months or result in earlier introduction of antiviral therapy.

Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled Study

2007 ◽  
Vol 132 (5) ◽  
pp. 1746-1756 ◽  
Author(s):  
José A. Carrión ◽  
Miquel Navasa ◽  
Montserrat García–Retortillo ◽  
Juan Carlos García–Pagan ◽  
Gonzalo Crespo ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Randomized Controlled Study ◽  
Controlled Study ◽  
Randomized Controlled ◽  
Hepatitis C Recurrence

scholarly journals Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany

2018 ◽  
Vol 69 (4) ◽  
pp. 982-984 ◽  
Author(s):  
Kerstin Herzer ◽  
Guido Gerken ◽  
Daniela Kroy ◽  
Frank Tacke ◽  
Julius Plewe ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Antiviral Therapy ◽  
Direct Acting Antiviral ◽  
Direct Acting

Liver Transplantation and Hepatitis C Virus: Systematic Review of Antiviral Therapy

2005 ◽  
Vol 79 (3) ◽  
pp. 261-268 ◽  
Author(s):  
Christos Triantos ◽  
Dimitrios Samonakis ◽  
Rosa Stigliano ◽  
Ulrich Thalheimer ◽  
David Patch ◽  
...  
Keyword(s):  
Systematic Review ◽  
Liver Transplantation ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Therapy
Sign in / Sign up

Export Citation Format

Share Document